| FDA Reviewers Flag Cancer Risk in Diabetes Drug - MedPage Today |
|
|
MedPage Today Dapagliflozin is an inhibitor of the sodium glucose cotransporter-2 (SGLT2) which works by increasing renal glucose elimination, allowing more sugar to be excreted with urine rather than being absorbed into the bloodstream. |